Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 6/20 | 1.00 |
| ▸ | F10 | P00742 | 4/20 | 1.00 |
| ▸ | PRMT1 | Q99873 | 6/20 | 0.59 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.49 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.49 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5028046 | 0.98 | F2 (0.97) | F2F10PRMT1TPSAB1TPSD1 | |
| SCHEMBL5030493 | 0.93 | F2 (0.88) | F2F10PRMT1TPSAB1TPSD1 | |
| SCHEMBL5028071 | 0.93 | F2 (0.88) | F2F10PRMT1 | |
| Hydrochloric Acid SCHEMBL5034703 | 0.92 | F2 (0.85) | F2F10PRMT1 | |
| Hydrochloric Acid SCHEMBL5034833 | 0.92 | F2 (0.85) | F2F10PRMT1 | |
| SCHEMBL5032861 | 0.92 | F2 (0.85) | F2F10PRMT1TPSAB1TPSD1 | |
| SCHEMBL7979967 | 0.92 | F2 (0.85) | F2F10PRMT1TPSAB1TPSD1 | |
| Hydrochloric Acid SCHEMBL5031493 | 0.91 | F2 (0.82) | F2F10PRMT1TPSAB1TPSD1 | |
| SCHEMBL5034730 | 0.90 | F2 (0.81) | F2F10PRMT1TPSAB1TPSD1 | |
| Hydrochloric Acid SCHEMBL5028092 | 0.88 | F2 (0.79) | F2F10PRMT1TPSAB1TPSD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1689732-A4 | CATIONIC SUBSTITUTED BENZOFURANS AS ANTIMICROBIAL AGENTS | UNIV NORTH CAROLINA (US) | 2008-10-22 | — | — | EP | claimed |
| US-20080114047-A1 | Cationic substituted benzofurans as antimicrobial agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-05-15 | — | — | US | claimed |
| EP-1689732-A2 | CATIONIC SUBSTITUTED BENZOFURANS AS ANTIMICROBIAL AGENTS | The University of North Carolina at Chapel Hill (US) | 2006-08-16 | — | — | EP | claimed |
| US-20050197378-A1 | Cationic substituted benzofurans as antimicrobial agents | TIDWELL RICHARD R (US) | 2005-09-08 | — | — | US | claimed |
| WO-2005055935-A2 | CATIONIC SUBSTITUTED BENZOFURANS AS ANTIMICROBIAL AGENTS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2005-06-23 | — | — | WO | claimed |
| US-5990079-A | INDWELLING INTRAVASCULAR DEVICE COMPRISING FACTOR XA AND BIOLOGICALLY ACTIVE PEPTIDE FRAGMENTS THEREOF WHICH HAVE BEEN TRANSIENTLY INACTIVATED; THE FACTOR XA GENERATES AN ACTIVE FORM IN THE PRESENCE OF SERUM; INCREASED HALF-LIFE IN BLOOD | COR THERAPEUTICS INC. (US) | 1999-11-23 | — | — | US | claimed |
| US-5968897-A | CARDIOVASCULAR DISORDERS AND BLOOD FACTORS | COR THERAPEUTICS, INC. (US) | 1999-10-19 | — | — | US | claimed |
| EP-1945209-B1 | BROAD SPECTRUM ANTIBACTERIAL COMPOUNDS | US GOV AS REPRESENTED BY THE SECRETARY OF THE UNITED STATES ARMY AND THE U S ARMY MEDICAL RESEARCH (US) | 2018-05-30 | — | — | EP | disclosed |
| US-20170182049-A1 | NOVEL THERAPEUTICS FOR BRAIN CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-06-29 | — | — | US | disclosed |
| US-20170182049-A1 | NOVEL THERAPEUTICS FOR BRAIN CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-06-29 | — | — | US | disclosed |
| US-8389261-B2 | Method of isolation and purification of trypsin from pronase protease and use thereof | BAXTER HEALTHCARE S.A. (CH) | 2013-03-05 | — | — | US | disclosed |
| US-20120003691-A1 | METHOD OF ISOLATION AND PURIFICATION OF TRYPSIN FROM PRONASE PROTEASE AND USE THEREOF | BAXTER HEALTHCARE S.A. (CH) | 2012-01-05 | — | — | US | disclosed |
| EP-1456228-B1 | METHOD OF ISOLATION AND PURIFICATION OF TRYPSIN FROM PRONASE AND USE THEREOF | BAXTER HEALTHCARE SA (CH) | 2011-05-04 | — | — | EP | disclosed |
| US-5602233-A | ACTIVATION AND DEACTIVATION | COR THERAPEUTICS, INC. (US) | 1997-02-11 | — | — | US | disclosed |
| US-5589572-A | Process for production of inhibited forms of activated blood factors | COR THERAPEUTICS, INC. (US) | 1996-12-31 | — | — | US | disclosed |
| US-5589571-A | Process for production of inhibited forms of activated blood factors | COR THERAPEUTICS, INC. (US) | 1996-12-31 | — | — | US | disclosed |
| US-5583107-A | ACYLATED BLOOD FACTOR XA AS TREATMENT FOR HEMOPHILIA | COR THERAPEUTICS, INC. (US) | 1996-12-10 | — | — | US | disclosed |
| US-5576343-A | ANTICOAGULANTS; BLOOD-COAGULATION FACTOR X INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1996-11-19 | — | — | US | disclosed |
| EP-0540051-B1 | Aromatic amidine derivatives and salts thereof | DAIICHI SEIYAKU CO (JP) | 1996-04-03 | — | — | EP | disclosed |
| EP-0540051-A1 | Aromatic amidine derivatives and salts thereof | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1993-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114047-A1 | Cationic substituted benzofurans as antimicrobial agents | BET1, ARG2, BRDT | F2 2791/4885F10 2781/4885PRMT1 1394/4885 |
| US-20050197378-A1 | Cationic substituted benzofurans as antimicrobial agents | BET1, ARG2, BRDT | F2 2791/4885F10 2781/4885PRMT1 1394/4885 |
| US-20170182049-A1 | NOVEL THERAPEUTICS FOR BRAIN CANCER | ING2, GMFG, PLP2 | F2 4794/4885F10 3374/4885PRMT1 2298/4885 |
| US-20120003691-A1 | METHOD OF ISOLATION AND PURIFICATION OF TRYPSIN FROM PRONASE PROTEASE AND USE THEREOF | PRSS3, RNPEP, NPEPPS | F2 1298/4885F10 2072/4885PRMT1 3339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.